Global Nasopharyngeal Carcinoma Market Size, Share, and COVID-19 Impact Analysis, By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Other Therapy), By End Users (Hospitals & Clinics, Ambulatory Surgery Centers, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 - 2030

Industry: Healthcare


Global Nasopharyngeal Carcinoma Market Forecasts to 2030

  • The Market is Growing at a CAGR of 5.6% from 2021 to 2030
  • The Worldwide Nasopharyngeal Cancer Market is expected to reach multimillion by 2030
  • Asia Pacific expected To Grow the fastest during the forecast period

Global Nasopharyngeal Carcinoma Market

Get more details on this report -

Request Free Sample PDF

The Global Nasopharyngeal Carcinoma Market is expected to reach multimillion by 2030, at a CAGR of 5.6 % during the forecast period 2021-2030.  Due to increasing patient count of nasopharyngeal cancer has grown significantly at a strong CAGR during the forecast period.


Market Overview

Nasopharyngeal carcinoma is a rare therapy for cancer that appears in the nasopharynx. Nasopharynx is located at the base of the skull & directly above the roof of the mouth. The symptoms which are considered in nasopharyngeal carcinoma are a sore throat, lump in the nose or neck, difficulty in breathing or speaking, difficulty in hearing, pain or ringing in the ear, or headaches. Nasopharyngeal carcinoma begins in squamous cells that track the nasopharynx. Nasopharyngeal cancers are diagnosed by different techniques such as EBV antibody test, X-ray, ultrasound, endoscopy, biopsy, CT scan, MRI, PET scan, or PET-CT scan.


In 2022, According to World Cancer Research Fund International (WCRF) data updated, nasopharyngeal carcinoma is the 22nd most common cancer in the world, ranking 22nd among cancers in women and 18th among cancers in men. According to the WCRF, approximately 145,120 new NPC cases will be examined worldwide in 2020. For Instance, According to the National Center for Biotechnology Information, the incidence of nasopharyngeal carcinoma differs according to geography, where 81% of new cases are observed in Asia, 8% in Africa, and only 10% are diagnosed in the rest of the world.


Report Coverage

This research report categorizes the market for Global Nasopharyngeal Carcinoma Market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Global Nasopharyngeal Carcinoma Market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the market.



Global Nasopharyngeal Carcinoma Market Report Coverage

Report CoverageDetails
Base Year:2021
Forecast Period:2021-2030
Forecast Period CAGR 2021-2030 :5.6%
Historical Data for:2017-2020
No. of Pages:200
Tables, Charts & Figures:120
Segments covered:By Therapy, By End Users, By Region, COVID-19 Impact Analysis
Companies covered::Biocon Limited, Bristol Myers Squibb Company, Cyclacel Pharmaceuticals, F. Hoffman La-Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer, Inc., GlaxoSmithKline (GSK) PLC, Sanofi, Theravectys SA, Eli Lilly And Company, Roche, BioDiem
Pitfalls & Challenges:COVID-19 Empact, Challenge, Future, Growth, & Analysis

Get more details on this report -

Request Free Sample PDF

Driving Factors

The global nasopharyngeal carcinoma market growth is expanding due to rising in the number of cases of nasopharyngeal carcinoma and growing awareness of treatment and diagnosis among the general public, which can both drive the market growth. Moreover, the key driving factors for nasopharyngeal carcinoma treatment market include the increasing geriatric population, rise in consumption of tobacco, increasing health awareness, and changing lifestyle. Also, in the developing region, the trend is likely to be seen where healthcare expenditure is increasing at a significant rate and the rapid adoption of technologies in healthcare presumptions is expected to grow the market over the period. Whereas the rising government spending on public healthcare, growing clinical trials & cancer research activities create profitable opportunities for future market growth. Research studies conducted by researchers and healthcare providers, to develop better treatment option, is further expected to propel the growth of the nasopharyngeal carcinoma treatment market.


Restraining Factors

The factors which are restraining the growth of the market includes, the high cost of therapeutic procedures such as chemotherapy, surgeries, and radiation therapies, results in out-of-pocket expenditure among non-insured nasopharyngeal carcinoma patient. Also, the side effects of the drug which are prescribed for the treatment of nasopharyngeal carcinoma can restrain the growth of the market.


Market Segmentation

 In 2021, the chemotherapy segment is witnessing growth in the market during the forecast period.

Based on the therapy, global nasopharyngeal carcinoma is segmented into chemotherapy, immunotherapy, radiation therapy, and others. Among these, chemotherapy is witnessing the market during the forecast period. Due to the rising incidence of nasopharyngeal carcinoma and new product launches, the chemotherapy segment is composed to witness growth over the forecast period. In April 2022, a research article published by the American Society of Clinical Oncology (ASCO) reported that the treatment for people with repeated or metastatic nasopharyngeal carcinoma is a combination of using gemcitabine (Gemzar) and cisplatin (available as a generic drug), as per the researchers, when Tislelizumab used in combination with chemotherapy, it helps people with advanced nasopharyngeal carcinoma live longer.


In 2021, hospitals & clinics has projected the largest market share during the forecast period

Based on end users, the global nasopharyngeal carcinoma market is categorized into hospitals & clinics, ambulatory surgery centers electronics and others. The hospitals & clinics segment accounted for the largest market share during the forecast period owing to the fast adoption of technologies is expected to boost the nasopharyngeal carcinoma market. Moreover, the availability of nasopharyngeal carcinoma treatments and procedures is easily available in the developed region has increased the demand for the nasopharyngeal carcinoma market. Also, the key market players are heavily investing in emerging regions to provide effective treatment solutions for higher healthcare quality, greater productivity, and better patient outcomes.


Regional Segment Analysis of the Global Nasopharyngeal Carcinoma Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)


North America is influencing the market over the forecast period.


Global Nasopharyngeal Carcinoma Market

Get more details on this report -

Request Free Sample PDF


North America is expected to dominate the market during the forecast period owing to the presence of key market players, which leads to technological advancements and delivers new products. Moreover, rising cases of nasopharyngeal carcinoma and high awareness among the population towards diagnosis & treatment in North American countries drive the growth of the global nasopharyngeal carcinoma market over the forecast period. Moreover, in February 2022, an article published by the journal Cancer Medicine has reported that Mexico has a significant increase in NPC cases over the past decennium. As a result, rising carcinoma cases are increasing the demand for nasopharyngeal carcinoma drugs and thus propelling the growth of the studied market in this region.


Asia-Pacific is expected to grow with the highest CAGR during the forecast period, as a result in terms of revenue and due to increasing research and development expenditure & clinical trials associated with growing product approval. The population of east Asia was found to be more susceptible to nasopharyngeal carcinoma.


Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the Global Nasopharyngeal Carcinoma Market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.


List of Key Companies

  • Biocon Limited
  • Bristol Myers Squibb Company
  • Cyclacel Pharmaceuticals
  • F. Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • GlaxoSmithKline (GSK) PLC
  • Sanofi
  • Theravectys SA
  • Eli Lilly And Company
  • Roche
  • BioDiem


Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)


Recent Developments

  • In January 2022, Wistar Institute launched a phase 2 trial investigating the safety and efficacy of the oral inhibitor VK-2019 in patients with advanced Epstein-Barr virus-positive nasopharyngeal carcinoma, which is a rare type of head and neck cancer lymphoma, this trial is led by the researchers at the Stanford university school of medicine.


  • In May 2021, The Head and Neck Cancer Alliance (HNCA) and PDS Biotechnology Corporation formed a partnership, aims that to increase awareness of new and developing treatment options for people who have been diagnosed with HPV-related head and neck cancer, including clinical studies that are currently being conducted.


  • In June 2022, KMC clinics in Kolkata, India, started cancer screening, including nasopharyngeal cancer under the head and neck division. The screening program was launched in collaboration with the Indian Medical Association (IMA), the Indian Dental Association (IDA), and Medica Super specialty Hospital. And it is expected to be carried out almost 16 centers under KMC.


Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global nasopharyngeal carcinoma market based on the below-mentioned segments:


Global Nasopharyngeal Carcinoma Market, By Types

  • Non-keratinizing undifferentiated carcinoma
  • Non-keratinizing differentiated carcinoma
  • Keratinizing squamous cell carcinoma


Global Nasopharyngeal Carcinoma Market, By Therapy

  • Chemotherapy
  • Immunotherapy
  • Radiation therapy
  • Other therapy


Global Nasopharyngeal Carcinoma Market, By End Users

  • Hospitals & clinics
  • Ambulatory surgery Centers
  • Cancer Treatment & Rehabilitation Centers 
  • Others


Global Nasopharyngeal Carcinoma Market, Regional Analysis

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies